Norwegian Population-Based Study of Long-Term Effects, Safety, and Predictors of Response of VNS Treatment in Drug-Resistant Epilepsy: The NORPulse Study

2021 ◽  
Author(s):  
Konstantin Hrisimirov Kostov ◽  
Hrisimir Kostadinov Kostov ◽  
Pål Gunnar Larsson ◽  
Oliver Henning ◽  
Christian Alexander Cornelius Eckmann ◽  
...  
Keyword(s):  
Population Based ◽  
Drug Resistant ◽  
Long Term Effects ◽  
Population Based Study ◽  
Predictors Of Response ◽  
Norwegian Population ◽  
Drug Resistant Epilepsy

scholarly journals Norwegian population‐based study of long‐term effects, safety, and predictors of response of vagus nerve stimulation treatment in drug‐resistant epilepsy: The NORPulse study

Epilepsia ◽  
2021 ◽  
Author(s):  
Konstantin H. Kostov ◽  
Hrisimir Kostov ◽  
Pål Gunnar Larsson ◽  
Oliver Henning ◽  
Christian Alexander Cornelius Eckmann ◽  
...  
Keyword(s):  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Population Based ◽  
Drug Resistant ◽  
Long Term Effects ◽  
Population Based Study ◽  
Predictors Of Response ◽  
Norwegian Population ◽  
Drug Resistant Epilepsy

Long-term effects of migraine on cognitive function: A population-based study of Danish twins

Neurology ◽  
2005 ◽  
Vol 64 (4) ◽  
pp. 600-607 ◽  
Author(s):  
D. Gaist ◽  
L. Pedersen ◽  
C. Madsen ◽  
I. Tsiropoulos ◽  
S. Bak ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Population Based ◽  
Long Term Effects ◽  
Population Based Study

Effect of copayment policies on initial medication non-adherence according to income: a population-based study

2018 ◽  
Vol 27 (11) ◽  
pp. 878-891 ◽  
Author(s):  
Ignacio Aznar-Lou ◽  
Anton Pottegård ◽  
Ana Fernández ◽  
María Teresa Peñarrubia-María ◽  
Antoni Serrano-Blanco ◽  
...  
Keyword(s):  
Low Income ◽  
Population Based ◽  
Free Access ◽  
Long Term Effects ◽  
Access To Health Services ◽  
Population Based Study ◽  
Middle Income ◽  
The Impact ◽  
Initial Medication

ObjectiveCopayment policies aim to reduce the burden of medication expenditure but may affect adherence and generate inequities in access to healthcare. The objective was to evaluate the impact of two copayment measures on initial medication non-adherence (IMNA) in several medication groups and by income level.DesignA population-based study was conducted using real-world evidence.SettingPrimary care in Catalonia (Spain) where two separate copayment measures (fixed copayment and coinsurance) were introduced between 2011 and 2013.ParticipantEvery patient with a new prescription issued between 2011 and 2014 (3 million patients and 10 million prescriptions).OutcomesIMNA was estimated throughout dispensing and invoicing information. Changes in IMNA prevalence after the introduction of copayment policies (immediate level change and trend changes) were estimated through segmented logistic regression. The regression models were stratified by economic status and medication groups.ResultsBefore changes to copayment policies, IMNA prevalence remained stable. The introduction of a fixed copayment was followed by a statistically significant increase in IMNA in poor population, low/middle-income pensioners and low-income non-pensioners (OR from 1.047 to 1.370). In high-income populations, there was a large statistically non-significant increase. IMNA decreased in the low-income population after suspension of the fixed copayment and the introduction of a coinsurance policy that granted this population free access to medications (OR=0.676). Penicillins were least affected while analgesics were affected to the greatest extent. IMNA to medications for chronic conditions increased in low/middle-income pensioners.ConclusionEven nominal charge fixed copayment may generate inequities in access to health services. An anticipation effect and expenses associated with IMNA may have generated short-term costs. A reduction in copayment can protect from non-adherence and have positive, long-term effects. Copayment scenarios could have considerable long-term consequences for health and costs due to increased IMNA in medication for chronic physical conditions.

scholarly journals Comparison of early effects of PCV7, PCV10 and PCV13 on S. pneumoniae (SP) nasopharyngeal carriage in a population based study; the Palestinian-Israeli Collaborative Research (PICR)

2018 ◽  
Author(s):  
Rania Abu Seir ◽  
Kifaya Azmi ◽  
Ayob Hamdan ◽  
Hanan Namouz ◽  
Fuad Jaar ◽  
...  
Keyword(s):  
Collaborative Research ◽  
Population Based ◽  
Long Term Effects ◽  
Cross Sectional ◽  
Population Based Study ◽  
Health Authorities ◽  
Early Effects ◽  
East Jerusalem

AbstractBackgroundPneumococcal conjugate vaccines (PCVs), PCV10 and PCV13, are currently used in different countries. We have previously reported the effectiveness of PCV7, following its introduction in Israel and before PCVs were introduced in Palestine. Here, we extended the study and compared the initial impact of PCV10 to that of PCV7/13.MethodsFour cross-sectional surveys of S. pneumoniae carriage among children <5y through 2009-2014 were preformed among two proximate populations, living under two distinct health authorities, with different vaccination policies. In East-Jerusalem (EJ), PCV7 was implemented in 2009 and replaced by PCV13 in late 2010, while in Palestine (PA), PCV10 was implemented in 2011.ResultsA total of 1267 and 2414 children from EJ and PA were screened. Implementation of both PCV7 (in EJ) and PCV10 (in PA) did not affect overall S. pneumoniae carriage (∼30%), but resulted in a significant decrease in carriage of VT7 strains. In the pre-vaccine era, VT7/VT13 strains consisted 47.0%/62.0% and 41.2%/54.8% of pneumococci in EJ and PA, respectively. A 48.6% and 53.9% decrease was observed within 3 years of PCV7 implementation in EJ (p= 0.001) and PCV10 in PA (p<0.0001), respectively. These vaccination policies also resulted in ∼50% reduction in VT13-added serotypes especially 6A (from 11.0% to 0.0% (EJ) and 9.5% to 4.9% (PA)). Three years after PCV13 implementation in EJ, an additional 67% decrease in VT13 strains was observed, yet an increase in serotype 3 was observed (0.0% to 3.4%, p=0.056). The prevalence of non-VT13 strains increased during the study period from 38% and 45.3% to 89.8% and 70.7%, in EJ and in PA respectively.ConclusionsWithin the first three years following PCV implementation, we observed similar reductions in carriage of VT10 and VT13 strains with either vaccination policies, with no effect on overall carriage. Further follow-up is needed to compare the long-term effects.

No relation between biomarkers at age 47–49 and aortic diameter after 14–19 years of follow-up – a population-based study

VASA ◽  
2017 ◽  
Vol 46 (4) ◽  
pp. 291-295 ◽  
Author(s):  
Soumia Taimour ◽  
Moncef Zarrouk ◽  
Jan Holst ◽  
Olle Melander ◽  
Gunar Engström ◽  
...  
Keyword(s):  
Population Based ◽  
Aortic Diameter ◽  
Aortic Dilatation ◽  
Population Based Study ◽  
Reactive Protein ◽  
Abdominal Aortic ◽  
Long Term Follow Up ◽  
Old Men

Abstract. Background: Biomarkers reflecting diverse pathophysiological pathways may play an important role in the pathogenesis of abdominal aortic aneurysm (aortic diameter ≥30 mm, AAA), levels of many biomarkers are elevated and correlated to aortic diameter among 65-year-old men undergoing ultrasound (US) screening for AAA. Probands and methods: To evaluate potential relationships between biomarkers and aortic dilatation after long-term follow-up, levels of C-reactive protein (CRP), proneurotensin (PNT), copeptin (CPT), lipoprotein-associated phospholipase 2 (Lp-PLA2), cystatin C (Cyst C), midregional proatrial natriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM) were measured in 117 subjects (114 [97 %] men) aged 47–49 in a prospective population-based cohort study, and related to aortic diameter at US examination of the aorta after 14–19 years of follow-up. Results: Biomarker levels at baseline did not correlate with aortic diameter after 14–19 years of follow up (CRP [r = 0.153], PNT [r = 0.070], CPT [r = –.156], Lp-PLA2 [r = .024], Cyst C [r = –.015], MR-proANP [r = 0.014], MR-proADM [r = –.117]). Adjusting for age and smoking at baseline in a linear regression model did not reveal any significant correlations. Conclusions: Tested biomarker levels at age 47–49 were not associated with aortic diameter at ultrasound examination after 14–19 years of follow-up. If there are relationships between these biomarkers and aortic dilatation, they are not relevant until closer to AAA diagnosis.

Sign in / Sign up

Export Citation Format

Share Document